On September 25, 2018 Orion Biotechnology Canada Ltd., a developer of novel medical treatments, reported that its subsidiary, Orion Biotechnology Switzerland Sàrl, has successfully closed a transaction with the Mintaka Medical Research Foundation for the acquisition of the 5P12-RANTES molecule (Press release, Orion Biotechnology, SEP 5, 2018, View Source [SID1234530101]) . 5P12-RANTES is a potent CCR5 chemokine antagonist which Orion will develop in a number of areas, including; immuno-oncology, multiple sclerosis and HIV prevention.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The acquisition includes its worldwide patent portfolio, and has resulted in a partnership with the Geneva, Switzerland based Mintaka Medical Research Foundation, and the Wellcome Trust of London, England. No financial details of the transaction were released.
"We are thrilled to add the enormous potential of the 5P12-RANTES portfolio to our pipeline" said Mark Groper, President and CEO of Orion Biotechnology. "It adds depth to our pipeline, strengthens our intellectual property portfolio, and provides the basis for the development of several additional novel immunotherapies".
"I’m excited that we were able to successfully form this partnership with Orion Biotechnology" said Robin Offord, Executive Director of the Mintaka Medical Research Foundation. "Mintaka looks forward to continuing its work on humanitarian (anti-HIV) uses of 5P12-RANTES with the help of the highly innovative and capable team at Orion and the substantial resources that they bring to the table. Also, 5P12-RANTES has surprised us all by its potential in a wide range of other medical indications and Orion is well placed to exploit these applications to the full".
Daniel Gill, from Wellcome’s Innovations team said: "HIV remains a significant global health issue and we are pleased to continue our collaboration on the development of 5P12-RANTES with Orion Biotechnology. 5P12-RANTES has significant potential in other areas of unmet need and we are excited that Orion will expand development of the molecule in other therapeutic areas such as immune-oncology and multiple sclerosis."